<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.urologytimes.com/view/nccn-recommends-ctdna-mrd-testing-to-guide-adjuvant-treatment-post-cystectomy</loc><lastmod>2026-06-24T17:00:00Z</lastmod><news:news><news:publication_date>2026-06-24T17:00:00Z</news:publication_date>
        <news:title><![CDATA[NCCN recommends ctDNA-MRD testing to guide adjuvant treatment post-cystectomy ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/real-time-cavitation-monitoring-drives-break-wave-s-renal-hematoma-safety-advantage</loc><lastmod>2026-06-24T16:47:58.929Z</lastmod><news:news><news:publication_date>2026-06-24T16:47:58.929Z</news:publication_date>
        <news:title><![CDATA[Real-time cavitation monitoring drives Break Wave's renal hematoma safety advantage]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/european-commission-approves-perioperative-ev-pembrolizumab-for-cisplatin-ineligible-mibc</loc><lastmod>2026-06-24T14:10:00Z</lastmod><news:news><news:publication_date>2026-06-24T14:10:00Z</news:publication_date>
        <news:title><![CDATA[European Commission approves perioperative EV/pembrolizumab for cisplatin-ineligible MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fred-saad-md-highlights-psa-end-points-from-the-phase-3-psmaddition-trial</loc><lastmod>2026-06-24T12:45:00Z</lastmod><news:news><news:publication_date>2026-06-24T12:45:00Z</news:publication_date>
        <news:title><![CDATA[Fred Saad, MD, highlights PSA end points from the phase 3 PSMAddition trial]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/from-guideline-to-practice-bridging-the-3-gaps-in-oab</loc><lastmod>2026-06-24T12:20:00Z</lastmod><news:news><news:publication_date>2026-06-24T12:20:00Z</news:publication_date>
        <news:title><![CDATA[From Guideline to Practice: Bridging the 3 Gaps in OAB]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/onabotulinumtoxina-for-oab-in-practice</loc><lastmod>2026-06-24T12:15:00Z</lastmod><news:news><news:publication_date>2026-06-24T12:15:00Z</news:publication_date>
        <news:title><![CDATA[OnabotulinumtoxinA for OAB in Practice]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/minimally-invasive-therapies-for-oab-what-the-guidelines-say</loc><lastmod>2026-06-24T12:10:00Z</lastmod><news:news><news:publication_date>2026-06-24T12:10:00Z</news:publication_date>
        <news:title><![CDATA[Minimally Invasive Therapies for OAB: What the Guidelines Say]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/non-invasive-and-pharmacologic-approaches-to-treating-oab</loc><lastmod>2026-06-24T12:05:00Z</lastmod><news:news><news:publication_date>2026-06-24T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Non-Invasive and Pharmacologic Approaches to Treating OAB]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/lymph-node-dissection-following-systemic-therapy-in-mibc</loc><lastmod>2026-06-24T12:05:00Z</lastmod><news:news><news:publication_date>2026-06-24T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Lymph Node Dissection Following Systemic Therapy in MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/nodal-disease-and-surgical-decision-making-in-mibc</loc><lastmod>2026-06-24T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-24T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Nodal Disease and Surgical Decision-Making in MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/oab-burden-diagnosis-and-the-guideline-s-new-framework</loc><lastmod>2026-06-24T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-24T12:00:00Z</news:publication_date>
        <news:title><![CDATA[OAB: Burden, Diagnosis, and the Guideline's New Framework]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/mina-fam-md-highlights-significance-of-tebipenem-pivoxil-approval-for-cuti</loc><lastmod>2026-06-23T18:30:00Z</lastmod><news:news><news:publication_date>2026-06-23T18:30:00Z</news:publication_date>
        <news:title><![CDATA[Mina Fam, MD, highlights significance of tebipenem pivoxil approval for cUTI]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/enzalutamide-plus-talazoparib-demonstrates-clinical-activity-in-mhspc</loc><lastmod>2026-06-23T17:45:00Z</lastmod><news:news><news:publication_date>2026-06-23T17:45:00Z</news:publication_date>
        <news:title><![CDATA[Enzalutamide plus talazoparib demonstrates clinical activity in mHSPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/pearls-perspectives-the-power-of-advocacy-in-sexual-medicine-with-rachel-rubin-md</loc><lastmod>2026-06-23T13:00:00Z</lastmod><news:news><news:publication_date>2026-06-23T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/microbial-dysbiosis-may-predict-response-to-cbm588-in-mrcc</loc><lastmod>2026-06-22T19:05:07.025Z</lastmod><news:news><news:publication_date>2026-06-22T19:05:07.025Z</news:publication_date>
        <news:title><![CDATA[Microbial dysbiosis may predict response to CBM588 in mRCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/eugene-pietzak-md-on-pembrolizumab-plus-bcg-for-bcg-na-ve-very-high-risk-t1-nmibc</loc><lastmod>2026-06-22T17:30:00Z</lastmod><news:news><news:publication_date>2026-06-22T17:30:00Z</news:publication_date>
        <news:title><![CDATA[Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/unmet-needs-and-emerging-solutions-in-mri-guided-prostate-cancer-care</loc><lastmod>2026-06-22T16:31:57.841Z</lastmod><news:news><news:publication_date>2026-06-22T16:31:57.841Z</news:publication_date>
        <news:title><![CDATA[Unmet needs and emerging solutions in MRI-guided prostate cancer care]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/retrospective-study-suggests-differences-in-oab-therapy-persistence-among-older-adults</loc><lastmod>2026-06-20T10:00:00Z</lastmod><news:news><news:publication_date>2026-06-20T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Retrospective study suggests differences in OAB therapy persistence among older adults]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/sandip-prasad-md-highlights-3-year-data-on-mitomycin-for-intravesical-solution-for-lg-ir-nmibc</loc><lastmod>2026-06-19T17:15:00Z</lastmod><news:news><news:publication_date>2026-06-19T17:15:00Z</news:publication_date>
        <news:title><![CDATA[Sandip Prasad, MD, highlights 3-year data on mitomycin for intravesical solution for LG-IR-NMIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/the-uroonc-minute-keeping-patients-engaged-in-active-surveillance-with-lourdes-guerrios-rivera-md-msc</loc><lastmod>2026-06-19T15:50:53.395Z</lastmod><news:news><news:publication_date>2026-06-19T15:50:53.395Z</news:publication_date>
        <news:title><![CDATA[The UroOnc Minute: Keeping Patients Engaged in Active Surveillance, With Lourdes Guerrios-Rivera, MD, MSc]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/hhs-requests-testosterone-therapy-label-updates-citing-new-safety-data</loc><lastmod>2026-06-19T13:05:00Z</lastmod><news:news><news:publication_date>2026-06-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[HHS requests testosterone therapy label updates, citing new safety data]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/in-resected-rcc-durvalumab-tremelimumab-combo-bests-monotherapy-on-dfs</loc><lastmod>2026-06-18T19:00:00Z</lastmod><news:news><news:publication_date>2026-06-18T19:00:00Z</news:publication_date>
        <news:title><![CDATA[In resected RCC, durvalumab/tremelimumab combo bests monotherapy on DFS]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/andrew-j-armstrong-md-msc-discusses-study-of-chemoimmunotherapy-in-nepc-avpc</loc><lastmod>2026-06-18T15:30:00Z</lastmod><news:news><news:publication_date>2026-06-18T15:30:00Z</news:publication_date>
        <news:title><![CDATA[Andrew J. Armstrong, MD, MSc, discusses study of chemoimmunotherapy in NEPC/AVPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-gives-nod-to-feasibility-study-of-nanoknife-ire-for-benign-prostatic-hyperplasia</loc><lastmod>2026-06-18T13:55:00Z</lastmod><news:news><news:publication_date>2026-06-18T13:55:00Z</news:publication_date>
        <news:title><![CDATA[FDA gives nod to feasibility study of NanoKnife IRE for benign prostatic hyperplasia]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/the-arteraai-prostate-test-what-it-is-and-how-it-works</loc><lastmod>2026-06-18T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-18T12:00:00Z</news:publication_date>
        <news:title><![CDATA[The ArteraAI Prostate Test: What It Is and How It Works]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/preserving-quality-of-life-in-metastatic-castration-sensitive-prostate-cancer</loc><lastmod>2026-06-18T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-18T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Preserving Quality of Life in Metastatic Castration-Sensitive Prostate Cancer ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/efficacy-results-rpfs-and-overall-survival-in-arasec</loc><lastmod>2026-06-18T04:00:00Z</lastmod><news:news><news:publication_date>2026-06-18T04:00:00Z</news:publication_date>
        <news:title><![CDATA[Efficacy Results: rPFS and Overall Survival in ARASEC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/pearls-perspectives-shaping-the-future-of-urology-with-thomas-f-stringer-md-facs</loc><lastmod>2026-06-17T18:05:34.999Z</lastmod><news:news><news:publication_date>2026-06-17T18:05:34.999Z</news:publication_date>
        <news:title><![CDATA[Pearls & Perspectives: Shaping the Future of Urology, With Thomas F. Stringer, MD, FACS]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-approves-tebipenem-pivoxil-for-complicated-urinary-tract-infections</loc><lastmod>2026-06-17T15:41:14.475Z</lastmod><news:news><news:publication_date>2026-06-17T15:41:14.475Z</news:publication_date>
        <news:title><![CDATA[FDA approves tebipenem pivoxil for complicated urinary tract infections]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/behind-the-fda-approval-capivasertib-mhspc-with-daniel-george-md</loc><lastmod>2026-06-17T15:15:00Z</lastmod><news:news><news:publication_date>2026-06-17T15:15:00Z</news:publication_date>
        <news:title><![CDATA[Behind the FDA approval of capivasertib for mHSPC, with Daniel J. George, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/surgical-perspectives-on-perioperative-therapy-in-mibc</loc><lastmod>2026-06-17T12:05:00Z</lastmod><news:news><news:publication_date>2026-06-17T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Surgical Perspectives on Perioperative Therapy in MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/how-to-schedule-patients-receiving-onabota-for-oab-to-maximize-adherence</loc><lastmod>2026-06-17T12:05:00Z</lastmod><news:news><news:publication_date>2026-06-17T12:05:00Z</news:publication_date>
        <news:title><![CDATA[How to Schedule Patients Receiving OnabotA for OAB to Maximize Adherence]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/reduced-injection-site-onabota-protocol-managing-complications</loc><lastmod>2026-06-17T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-17T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Reduced Injection-Site OnabotA Protocol: Managing Complications]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/putting-data-from-a-post-rp-multimodal-ai-prognostic-model-into-context</loc><lastmod>2026-06-17T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-17T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Putting Data from a Post-RP Multimodal AI Prognostic Model Into Context]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/surgical-timing-in-the-perioperative-era-of-mibc</loc><lastmod>2026-06-17T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-17T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Surgical Timing in the Perioperative Era of MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/jenny-guo-md-discusses-outcomes-hemi-holep-after-pelvic-radiation</loc><lastmod>2026-06-16T19:55:00Z</lastmod><news:news><news:publication_date>2026-06-16T19:55:00Z</news:publication_date>
        <news:title><![CDATA[Jenny Guo, MD, discusses outcomes with hemi-HoLEP after pelvic radiation]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/daniel-eun-md-on-telesurgery-ai-and-the-future-of-reconstructive-urology</loc><lastmod>2026-06-16T17:15:00Z</lastmod><news:news><news:publication_date>2026-06-16T17:15:00Z</news:publication_date>
        <news:title><![CDATA[Daniel Eun, MD, on telesurgery, AI, and the future of reconstructive urology]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/louise-emmett-md-phd-highlights-early-data-225ac-psma-617-mcrpc</loc><lastmod>2026-06-16T14:45:00Z</lastmod><news:news><news:publication_date>2026-06-16T14:45:00Z</news:publication_date>
        <news:title><![CDATA[Louise Emmett, MD, PhD, highlights early data on 225Ac-PSMA-617 in mCRPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/toni-choueiri-md-reacts-fda-approval-adjuvant-belzutifan-with-pembrolizumab-for-ccrcc</loc><lastmod>2026-06-15T18:00:00Z</lastmod><news:news><news:publication_date>2026-06-15T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/acou085-shows-promise-for-cisplatin-induced-hearing-loss-in-patients-with-testicular-cancer</loc><lastmod>2026-06-15T15:35:00Z</lastmod><news:news><news:publication_date>2026-06-15T15:35:00Z</news:publication_date>
        <news:title><![CDATA[ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/dean-elterman-md-highlights-efficacy-and-safety-data-on-the-zenflow-prostatic-spring</loc><lastmod>2026-06-15T14:15:00Z</lastmod><news:news><news:publication_date>2026-06-15T14:15:00Z</news:publication_date>
        <news:title><![CDATA[Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-approves-capivasertib-plus-abiraterone-and-prednisone-for-pten-deficient-mhspc</loc><lastmod>2026-06-12T18:40:47.185Z</lastmod><news:news><news:publication_date>2026-06-12T18:40:47.185Z</news:publication_date>
        <news:title><![CDATA[FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-approves-adjuvant-belzutifan-with-pembrolizumab-for-ccrcc</loc><lastmod>2026-06-12T17:45:00Z</lastmod><news:news><news:publication_date>2026-06-12T17:45:00Z</news:publication_date>
        <news:title><![CDATA[FDA approves adjuvant belzutifan with pembrolizumab for ccRCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/the-uroonc-minute-variant-histologies-in-bladder-cancer-with-carissa-chu-md</loc><lastmod>2026-06-12T12:50:00Z</lastmod><news:news><news:publication_date>2026-06-12T12:50:00Z</news:publication_date>
        <news:title><![CDATA[The UroOnc Minute: Variant Histologies in Bladder Cancer, With Carissa Chu, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/benjamin-lowentritt-md-reviews-real-world-testosterone-recovery-data-with-relugolix</loc><lastmod>2026-06-11T19:15:00Z</lastmod><news:news><news:publication_date>2026-06-11T19:15:00Z</news:publication_date>
        <news:title><![CDATA[Benjamin Lowentritt, MD, reviews real-world testosterone recovery data with relugolix]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/sabr-demonstrates-safety-and-local-control-in-primary-renal-cell-carcinoma</loc><lastmod>2026-06-11T16:45:00Z</lastmod><news:news><news:publication_date>2026-06-11T16:45:00Z</news:publication_date>
        <news:title><![CDATA[SABR demonstrates safety and local control in primary renal cell carcinoma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/jonathan-harper-md-shares-push-trial-findings-on-hydration-and-stone-recurrence</loc><lastmod>2026-06-11T14:15:00Z</lastmod><news:news><news:publication_date>2026-06-11T14:15:00Z</news:publication_date>
        <news:title><![CDATA[Jonathan Harper, MD, shares PUSH trial findings on hydration and stone recurrence]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/setting-the-stage-adt-in-intermediate-risk-prostate-cancer</loc><lastmod>2026-06-11T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-11T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Setting the Stage: ADT in Intermediate-Risk Prostate Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/navigating-comorbidities-and-treatment-decisions-in-metastatic-castration-sensitive-prostate-cancer</loc><lastmod>2026-06-11T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-11T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Navigating Comorbidities and Treatment Decisions in Metastatic Castration-Sensitive Prostate Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/propensity-score-matching-methodology-in-arasec</loc><lastmod>2026-06-11T04:00:00Z</lastmod><news:news><news:publication_date>2026-06-11T04:00:00Z</news:publication_date>
        <news:title><![CDATA[Propensity Score Matching Methodology in ARASEC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/onabotulinumtoxina-for-oab-efficacy-of-the-reduced-injection-site-protocol</loc><lastmod>2026-06-10T16:35:00Z</lastmod><news:news><news:publication_date>2026-06-10T16:35:00Z</news:publication_date>
        <news:title><![CDATA[OnabotulinumtoxinA for OAB: Efficacy of the Reduced Injection-Site Protocol]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/the-oab-treatment-landscape-and-how-to-choose-a-treatment</loc><lastmod>2026-06-10T16:30:00Z</lastmod><news:news><news:publication_date>2026-06-10T16:30:00Z</news:publication_date>
        <news:title><![CDATA[The OAB Treatment Landscape and How to Choose a Treatment]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-approves-generic-ga-68-psma-11-radiodiagnostic-for-prostate-cancer</loc><lastmod>2026-06-10T15:15:00Z</lastmod><news:news><news:publication_date>2026-06-10T15:15:00Z</news:publication_date>
        <news:title><![CDATA[FDA approves generic Ga-68 PSMA-11 radiodiagnostic for prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/kevin-zorn-md-on-selecting-among-different-mist-options-for-bph</loc><lastmod>2026-06-10T13:15:00Z</lastmod><news:news><news:publication_date>2026-06-10T13:15:00Z</news:publication_date>
        <news:title><![CDATA[Kevin Zorn, MD, on selecting among different MIST options for BPH]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/emerging-combination-perioperative-strategies-in-mibc</loc><lastmod>2026-06-10T12:05:00Z</lastmod><news:news><news:publication_date>2026-06-10T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Emerging Combination Perioperative Strategies in MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/addressing-unmet-needs-in-mibc</loc><lastmod>2026-06-10T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-10T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Addressing Unmet Needs in MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/clinical-application-of-mmai-score-in-patients-with-prostate-cancer</loc><lastmod>2026-06-10T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-10T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Clinical Application of MMAI Score in Patients with Prostate Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/pearls-perspectives-the-evolving-landscape-of-female-pelvic-health-with-annah-j-vollstedt-md</loc><lastmod>2026-06-09T16:15:35.146Z</lastmod><news:news><news:publication_date>2026-06-09T16:15:35.146Z</news:publication_date>
        <news:title><![CDATA[Pearls & Perspectives: The Evolving Landscape of Female Pelvic Health, With Annah J. Vollstedt, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/nicole-l-miller-md-facs-on-assessing-patients-after-bph-treatment-failure</loc><lastmod>2026-06-09T15:00:00Z</lastmod><news:news><news:publication_date>2026-06-09T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/published-data-show-dfs-benefit-with-aglatimagene-besadenovec-in-localized-prostate-cancer</loc><lastmod>2026-06-08T16:45:00Z</lastmod><news:news><news:publication_date>2026-06-08T16:45:00Z</news:publication_date>
        <news:title><![CDATA[Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/study-suggests-potential-diuretic-effect-with-nadofaragene-firadenovec</loc><lastmod>2026-06-08T15:00:00Z</lastmod><news:news><news:publication_date>2026-06-08T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Study suggests potential diuretic effect with nadofaragene firadenovec]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/clint-bahler-md-reflects-on-precision-diagnostics-and-focal-therapy-highlights-at-aua-2026</loc><lastmod>2026-06-05T19:55:00Z</lastmod><news:news><news:publication_date>2026-06-05T19:55:00Z</news:publication_date>
        <news:title><![CDATA[Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/the-uroonc-minute-mdt-for-oligometastatic-prostate-cancer-with-chad-tang-md</loc><lastmod>2026-06-05T14:00:00Z</lastmod><news:news><news:publication_date>2026-06-05T14:00:00Z</news:publication_date>
        <news:title><![CDATA[The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/rad-io-durvalumab-plus-chemoradiotherapy-is-feasible-in-mibc</loc><lastmod>2026-06-05T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-05T12:00:00Z</news:publication_date>
        <news:title><![CDATA[RAD-IO: Durvalumab plus chemoradiotherapy is feasible in MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-greenlights-pivotal-trial-of-separo-vessel-sealing-system-for-vasectomy</loc><lastmod>2026-06-04T16:55:40.776Z</lastmod><news:news><news:publication_date>2026-06-04T16:55:40.776Z</news:publication_date>
        <news:title><![CDATA[FDA greenlights pivotal trial of Separo Vessel Sealing System for vasectomy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/praful-ravi-mb-bchir-mrcp-psma-pet-during-initial-systemic-therapy-mhspc</loc><lastmod>2026-06-04T14:40:21.115Z</lastmod><news:news><news:publication_date>2026-06-04T14:40:21.115Z</news:publication_date>
        <news:title><![CDATA[Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/what-makes-the-synthetic-control-design-of-arasec-innovative</loc><lastmod>2026-06-04T04:00:00Z</lastmod><news:news><news:publication_date>2026-06-04T04:00:00Z</news:publication_date>
        <news:title><![CDATA[What Makes the Synthetic Control Design of ARASEC Innovative]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-updates-in-urology-may-2026</loc><lastmod>2026-06-03T18:15:00Z</lastmod><news:news><news:publication_date>2026-06-03T18:15:00Z</news:publication_date>
        <news:title><![CDATA[FDA updates in urology: May 2026 ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/comparing-perioperative-strategies-in-cisplatin-eligible-mibc</loc><lastmod>2026-06-03T17:00:00Z</lastmod><news:news><news:publication_date>2026-06-03T17:00:00Z</news:publication_date>
        <news:title><![CDATA[Comparing Perioperative Strategies in Cisplatin-Eligible MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/perioperative-therapy-expansion-in-cisplatin-ineligible-mibc</loc><lastmod>2026-06-03T16:55:00Z</lastmod><news:news><news:publication_date>2026-06-03T16:55:00Z</news:publication_date>
        <news:title><![CDATA[Perioperative Therapy Expansion in Cisplatin-Ineligible MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-approves-titan-prime-inflatable-penile-prosthesis</loc><lastmod>2026-06-03T15:50:00Z</lastmod><news:news><news:publication_date>2026-06-03T15:50:00Z</news:publication_date>
        <news:title><![CDATA[FDA approves Titan Prime Inflatable Penile Prosthesis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/pearls-perspectives-expanding-options-for-men-with-erectile-dysfunction-with-tom-riester</loc><lastmod>2026-06-03T13:00:00Z</lastmod><news:news><news:publication_date>2026-06-03T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Pearls & Perspectives: Expanding Options for Men With Erectile Dysfunction, With Tom Riester]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/how-a-post-rp-mmai-model-performed-in-a-long-term-survivor-population</loc><lastmod>2026-06-03T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-03T12:00:00Z</news:publication_date>
        <news:title><![CDATA[How a Post-RP MMAI Model Performed in a Long-Term Survivor Population]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/pedro-barata-md-phase-3-data-177lu-rosopatamab-mcrpc</loc><lastmod>2026-06-02T14:45:00Z</lastmod><news:news><news:publication_date>2026-06-02T14:45:00Z</news:publication_date>
        <news:title><![CDATA[Pedro Barata, MD, highlights phase 3 data on 177Lu-rosopatamab tetraxetan in mCRPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/phase-1-action-trial-establishes-rp2d-for-225ac-psma-617</loc><lastmod>2026-06-02T12:58:56.711Z</lastmod><news:news><news:publication_date>2026-06-02T12:58:56.711Z</news:publication_date>
        <news:title><![CDATA[Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/tanya-b-dorff-md-highlights-early-data-abbv-969-mcrpc</loc><lastmod>2026-06-01T21:05:07.490Z</lastmod><news:news><news:publication_date>2026-06-01T21:05:07.490Z</news:publication_date>
        <news:title><![CDATA[Tanya B. Dorff, MD, highlights early data on ABBV-969 in mCRPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/hrqol-is-preserved-with-perioperative-ev-plus-pembrolizumab-in-mibc</loc><lastmod>2026-06-01T17:40:18.875Z</lastmod><news:news><news:publication_date>2026-06-01T17:40:18.875Z</news:publication_date>
        <news:title><![CDATA[HRQoL is preserved with perioperative EV plus pembrolizumab in MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/kim-chi-md-sequencing-177lu-psma-617-and-docetaxel-mcrpc</loc><lastmod>2026-06-01T15:30:00Z</lastmod><news:news><news:publication_date>2026-06-01T15:30:00Z</news:publication_date>
        <news:title><![CDATA[Kim Chi, MD, on sequencing 177Lu-PSMA-617 and docetaxel in mCRPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-approves-cefepime-and-zidebactam-for-complicated-uti</loc><lastmod>2026-06-01T14:21:23.776Z</lastmod><news:news><news:publication_date>2026-06-01T14:21:23.776Z</news:publication_date>
        <news:title><![CDATA[FDA approves cefepime and zidebactam for complicated UTI]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/clinical-approaches-for-treatment-intensification-in-metastatic-castration-sensitive-prostate-cancer</loc><lastmod>2026-06-01T12:15:00Z</lastmod><news:news><news:publication_date>2026-06-01T12:15:00Z</news:publication_date>
        <news:title><![CDATA[Clinical Approaches for Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/indirect-trial-comparisons-in-metastatic-castration-sensitive-prostate-cancer</loc><lastmod>2026-06-01T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-01T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Indirect Trial Comparisons in Metastatic Castration-Sensitive Prostate Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/proteus-apalutamide-plus-adt-before-and-after-rp-cuts-metastasis-risk</loc><lastmod>2026-05-31T19:00:19.110Z</lastmod><news:news><news:publication_date>2026-05-31T19:00:19.110Z</news:publication_date>
        <news:title><![CDATA[PROTEUS: Apalutamide plus ADT before and after RP cuts metastasis risk]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/lucia-nappi-md-mir371-early-stage-testicular-cancer</loc><lastmod>2026-05-31T17:30:00Z</lastmod><news:news><news:publication_date>2026-05-31T17:30:00Z</news:publication_date>
        <news:title><![CDATA[Lucia Nappi, MD, highlights data on miR371 in early-stage testicular cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/ly4052031-shows-early-promise-in-post-ev-urothelial-cancer</loc><lastmod>2026-05-31T15:55:15.497Z</lastmod><news:news><news:publication_date>2026-05-31T15:55:15.497Z</news:publication_date>
        <news:title><![CDATA[LY4052031 shows early promise in post-EV urothelial cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/adjuvant-pembrolizumab-affects-fatigue-but-not-hrqol-in-muscle-invasive-uc</loc><lastmod>2026-05-31T14:39:15.809Z</lastmod><news:news><news:publication_date>2026-05-31T14:39:15.809Z</news:publication_date>
        <news:title><![CDATA[Adjuvant pembrolizumab affects fatigue but not HRQOL in muscle-invasive UC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/alicia-morgans-md-discusses-cognitive-effects-darolutamide-vs-enzalutamide-prostate-cancer</loc><lastmod>2026-05-31T14:30:00Z</lastmod><news:news><news:publication_date>2026-05-31T14:30:00Z</news:publication_date>
        <news:title><![CDATA[Alicia Morgans, MD, discusses cognitive effects of darolutamide vs enzalutamide in prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/talapro-3-talazoparib-plus-enzalutamide-improves-rpfs-hrr-gene-altered-mcspc</loc><lastmod>2026-05-31T12:00:00Z</lastmod><news:news><news:publication_date>2026-05-31T12:00:00Z</news:publication_date>
        <news:title><![CDATA[TALAPRO-3: Talazoparib plus enzalutamide improves rPFS in HRR gene-altered mCSPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/enzalutamide-associated-with-greater-cognitive-decline-than-darolutamide-in-advanced-prostate-cancer</loc><lastmod>2026-05-30T22:45:00Z</lastmod><news:news><news:publication_date>2026-05-30T22:45:00Z</news:publication_date>
        <news:title><![CDATA[Enzalutamide associated with greater cognitive decline than darolutamide in advanced prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/enzamet-decipher-score-may-refine-triplet-therapy-use-in-mhspc</loc><lastmod>2026-05-30T22:00:00Z</lastmod><news:news><news:publication_date>2026-05-30T22:00:00Z</news:publication_date>
        <news:title><![CDATA[ENZAMET: Decipher score may refine triplet therapy use in mHSPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/rana-mckay-md-on-radium-223-plus-cabozantinib-in-renal-cell-carcinoma</loc><lastmod>2026-05-30T20:50:32.169Z</lastmod><news:news><news:publication_date>2026-05-30T20:50:32.169Z</news:publication_date>
        <news:title><![CDATA[Rana McKay, MD, on radium-223 plus cabozantinib in renal cell carcinoma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/ev-p-maintains-os-benefit-at-3-5-years-in-metastatic-uc</loc><lastmod>2026-05-30T19:15:00Z</lastmod><news:news><news:publication_date>2026-05-30T19:15:00Z</news:publication_date>
        <news:title><![CDATA[EV+P maintains OS benefit at 3.5 years in metastatic UC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/sakk-06-19-rbcg-added-to-chemo-io-achieves-high-pcr-in-mibc</loc><lastmod>2026-05-30T17:34:49.316Z</lastmod><news:news><news:publication_date>2026-05-30T17:34:49.316Z</news:publication_date>
        <news:title><![CDATA[SAKK 06/19: rBCG added to chemo-IO achieves high pCR in MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/mark-fleming-md-and-manojkumar-bupathi-md-most-anticipated-gu-data-at-asco-2026</loc><lastmod>2026-05-30T17:30:00Z</lastmod><news:news><news:publication_date>2026-05-30T17:30:00Z</news:publication_date>
        <news:title><![CDATA[Mark Fleming, MD, and Manoj Bupathi, MD, discuss the most anticipated GU data at ASCO 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/updated-ev-302-analysis-continues-to-support-ev-p-for-locally-advanced-metastatic-urothelial-carcinoma</loc><lastmod>2026-05-30T13:00:00Z</lastmod><news:news><news:publication_date>2026-05-30T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Updated EV-302 analysis continues to support EV/P for locally advanced/metastatic urothelial carcinoma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/exome-based-ctdna-shows-low-sensitivity-for-recurrence-detection-in-adjuvant-ccrcc</loc><lastmod>2026-05-29T21:30:00Z</lastmod><news:news><news:publication_date>2026-05-29T21:30:00Z</news:publication_date>
        <news:title><![CDATA[Exome-based ctDNA shows low sensitivity for recurrence detection in adjuvant ccRCC ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/no-sse-fs-benefit-is-observed-with-radium-223-plus-cabozantinib-in-renal-cell-carcinoma</loc><lastmod>2026-05-29T20:27:44.866Z</lastmod><news:news><news:publication_date>2026-05-29T20:27:44.866Z</news:publication_date>
        <news:title><![CDATA[No SSE-FS benefit is observed with radium-223 plus cabozantinib in renal cell carcinoma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/objective-performance-indicators-bring-data-driven-feedback-to-robotic-surgery</loc><lastmod>2026-05-29T15:39:39.398Z</lastmod><news:news><news:publication_date>2026-05-29T15:39:39.398Z</news:publication_date>
        <news:title><![CDATA[Objective performance indicators bring data-driven feedback to robotic surgery]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/break-wave-lithotripsy-achieves-non-inferiority-to-shock-wave-in-pivotal-trial</loc><lastmod>2026-05-29T13:29:00Z</lastmod><news:news><news:publication_date>2026-05-29T13:29:00Z</news:publication_date>
        <news:title><![CDATA[Break Wave lithotripsy achieves non-inferiority to shock wave in pivotal trial]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/money-matters-how-can-you-plan-for-your-retirement-income-needs-</loc><lastmod>2026-05-29T12:04:52.434Z</lastmod><news:news><news:publication_date>2026-05-29T12:04:52.434Z</news:publication_date>
        <news:title><![CDATA[Money Matters: How can you plan for your retirement income needs?]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-approves-durvalumab-plus-bcg-for-bcg-naive-high-risk-nmibc</loc><lastmod>2026-05-28T17:30:00Z</lastmod><news:news><news:publication_date>2026-05-28T17:30:00Z</news:publication_date>
        <news:title><![CDATA[FDA approves durvalumab plus BCG for BCG-naïve, high-risk NMIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url></urlset>